Annual General Shareholders' Meeting 2021

Read more

INVESTORS

Latest news

Show more news

April 7, 2021

Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S.

Read more

April 2, 2021

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

Read more

March 9, 2021

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

Read more

Show more news

€5.3
billion

revenue

24000
employees

€606
million

R+D+i and capex investments

€5.3
billion

revenue

24000
employees

€606
million

R+D+i and capex investments

Integrated annual report

Review of the Grifols' strong financial performance and integration with environmental, social responsibility and corporate governance criteria.

Read more
Sustainable Development Goals

Learn about Grifols' efforts to achieve Sustainable Development Goals adopted by the United Nations.

Read more

ACTIVITY AGENDA

2021 May 21

Annual General meeting 2021

Second call – Expected to be held on this date

2021 May 20

Annual General meeting 2021

First call

2021 May 4

First quarter financial results 2021

Available before Spanish stock market opens

See more

2021 May 21

Annual General meeting 2021

Second call – Expected to be held on this date

2021 May 20

Annual General meeting 2021

First call

2021 May 4

First quarter financial results 2021

Available before Spanish stock market opens

See more

CONTACT

Av. de la Generalitat 152-158
Parc empresarial Can Sant Joan
08174 Sant Cugat del Vallès,
Barcelona – España
+34 93 571 02 21
inversores@grifols.com